08:00 , Feb 17, 2014 |  BioCentury  |  Finance

Funding the 3X3 plan

Funding the 3X3 plan Rather than take advantage of a piping hot IPO market, Melinta Therapeutics Inc. is using last week's private round to extract more value out of its delafloxacin antibiotic. The company plans...
02:21 , Feb 11, 2014 |  BC Extra  |  Financial News

Antibiotics play Melinta raises about $35 million

Melinta Therapeutics Inc. (New Haven, Conn.) raised about $35 million of a planned $70 million in a tranched venture round led by existing investor Vatera Healthcare Partners. New investor Falcon Flight participated along with undisclosed...
07:00 , Sep 23, 2013 |  BC Week In Review  |  Company News

Acusphere management update

Acusphere Inc. (Pink:ACUSD), Lexington, Mass.   Business: Diagnostic, Drug delivery   Hired: Mark Leuchtenberger as president, CEO and a director, formerly president, CEO and a director of Rib-X Pharmaceuticals Inc. ; he succeeds Co-Founder Serri...
07:00 , May 27, 2013 |  BC Week In Review  |  Clinical News

IV delafloxacin: Phase III started

Rib-X began the double-blind, international Phase III PROCEED trial to compare 300 mg IV delafloxacin twice daily for up to 28 doses vs. 15 mg/kg vancomycin plus 2 g IV aztreonam twice daily for up...
07:00 , Apr 8, 2013 |  BC Week In Review  |  Company News

Rib-X management update

Rib-X Pharmaceuticals Inc. , New Haven, Conn.   Business: Infectious   Hired: Michael Kenston as chief commercial officer, a newly created position, formerly VP of commercial analysis at Reata Pharmaceuticals Inc. ; Eugene Sun as...
07:00 , Apr 8, 2013 |  BC Week In Review  |  Company News

Rib-X board of directors update

Rib-X Pharmaceuticals Inc. , New Haven, Conn.   Business: Infectious   Appointed: Thomas Koestler, a director, as chairman; he replaces Mary Szela who becomes CEO  ...
07:00 , Apr 8, 2013 |  BioCentury  |  Finance

Company builder

Company builder Several months after Vatera Holdings became Rib-X Pharmaceuticals Inc. 's biggest backer, the firm has now installed a handpicked CEO and new commercial head. The moves suggest any plans for a public exit...
23:32 , Apr 3, 2013 |  BC Extra  |  Company News

Rib-X names new CEO

Rib-X Pharmaceuticals Inc. (New Haven, Conn.) named Chair Mary Szela as CEO on Wednesday, and made two new additions to the company's management team. Szela is former SVP of global strategic marketing and services of...
08:00 , Feb 25, 2013 |  BioCentury  |  Regulation

Limiting 'Limited-Use'

A new expedited limited-use drug approval pathway that was recommended by the President's Council of Advisors on Science and Technology and senior FDA officials is falling victim to concerns from big pharma companies that the...
08:00 , Jan 14, 2013 |  BC Week In Review  |  Company News

Rib-X board of directors update

Rib-X Pharmaceuticals Inc. , New Haven, Conn.   Business: Infectious   Appointed: Mary Szela as chair, formerly SVP of global strategic marketing and services of the pharmaceutical products group at Abbott Laboratories  ...